Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatalanib and Octreotide in Progressive Low-Grade Neuroendocrine Tumors
NCT00227773Phase 2Withdrawn
- Sponsor
- Eastern Cooperative Oncology Group
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vatalanib in Neuroendocrine Neoplasm (NEN), sponsored by Eastern Cooperative Oncology Group. Status: withdrawn.
02
Drugs
vatalanib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00227773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227773.